[{"address1": "Gateway, 1 Macquarie Place", "address2": "Level 36", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "phone": "61 2 8051 3043", "fax": "61 2 8051 3043", "website": "https://www.raceoncology.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on cancer care. Its lead product is bisantrene, a small molecule chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications; delivers cardioprotection; and improves anti-cancer activity in solid tumors. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of fat mass and obesity-associated protein (FTO). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Daniel  Tillett", "title": "Chief Executive Officer", "fiscalYear": 2024, "totalPay": 147661, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.83, "open": 0.83, "dayLow": 0.83, "dayHigh": 0.83, "regularMarketPreviousClose": 0.83, "regularMarketOpen": 0.83, "regularMarketDayLow": 0.83, "regularMarketDayHigh": 0.83, "beta": 1.743, "volume": 3, "regularMarketVolume": 3, "averageVolume": 129, "marketCap": 207885568, "fiftyTwoWeekLow": 0.83, "fiftyTwoWeekHigh": 1.45, "priceToSalesTrailing12Months": 51.926346, "fiftyDayAverage": 1.2752, "twoHundredDayAverage": 1.4063, "currency": "USD", "enterpriseValue": 190681840, "floatShares": 115923677, "sharesOutstanding": 170398000, "heldPercentInsiders": 0.36378, "bookValue": 0.108, "priceToBook": 11.296296, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -13819336, "trailingEps": -0.06, "enterpriseToRevenue": 47.629, "enterpriseToEbitda": -13.425, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "RAONF", "underlyingSymbol": "RAONF", "shortName": "RACE ONCOLOGY LTD", "longName": "Race Oncology Limited", "firstTradeDateEpochUtc": 1615300200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0b11adb6-158b-303c-8ed4-aefbef19df5c", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.22, "recommendationKey": "none", "totalCash": 17188828, "totalCashPerShare": 0.101, "ebitda": -14203376, "quickRatio": 9.257, "currentRatio": 9.323, "totalRevenue": 4003470, "revenuePerShare": 0.024, "returnOnAssets": -0.38633, "returnOnEquity": -0.63104, "freeCashflow": -4827357, "operatingCashflow": -9545579, "revenueGrowth": -1.0, "grossMargins": 0.34717998, "operatingMargins": -3.6179998, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]